Search Results - "Zani, Valter J"

Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis by Block, Geoffrey A, Martin, Kevin J, de Francisco, Angel L.M, Turner, Stewart A, Avram, Morrell M, Suranyi, Michael G, Hercz, Gavril, Cunningham, John, Abu-Alfa, Ali K, Messa, Piergiorgio, Coyne, Daniel W, Locatelli, Francesco, Cohen, Raphael M, Evenepoel, Pieter, Moe, Sharon M, Fournier, Albert, Braun, Johann, McCary, Laura C, Zani, Valter J, Olson, Kurt A, Drüeke, Tilman B, Goodman, William G

“…Hypercalcemia and hyperphosphatemia often complicate secondary hyperparathyroidism therapy in patients who are receiving dialysis. Unlike vitamin D and…”
Get full text

The OPTIMA Study: Assessing a New Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism by Messa, Piergiorgio, Macário, Fernando, Yaqoob, Magdi, Bouman, Koen, Braun, Johann, von Albertini, Beat, Brink, Hans, Maduell, Francisco, Graf, Helmut, Frazão, João M, Bos, Willem Jan, Torregrosa, Vicente, Saha, Heikki, Reichel, Helmut, Wilkie, Martin, Zani, Valter J, Molemans, Bart, Carter, Dave, Locatelli, Francesco

“…Cinacalcet, a novel calcimimetic, targets the calcium-sensing receptor to lower parathyroid hormone (PTH), calcium, and phosphorus levels in dialysis patients…”
Get full text

Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl by Moe, Sharon M., Cunningham, John, Bommer, Jürgen, Adler, Stephen, Rosansky, Steven J., Urena-Torres, Pablo, Albizem, Moetaz B., Guo, Matthew D., Zani, Valter J., Goodman, William G., Sprague, Stuart M.

“…Background. Patients with secondary hyperparathyroidism often require therapy that provides long-term control of parathyroid hormone concentrations without…”
Get full text

The effects of discontinuing cinacalcet at the time of kidney transplantation by Jadoul, Michel, Baños, Ana, Zani, Valter J, Hercz, Gavril

“…Background. The calcimimetic, cinacalcet, is approved for treating secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on…”
Get full text

Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet by Wilkie, Martin, Pontoriero, Giuseppe, Macário, Fernando, Yaqoob, Magdi, Bouman, Koen, Braun, Johann, von Albertini, Beat, Brink, Hans, Maduell, Francisco, Graf, Helmut, Frazão, João M, Bos, Willem Jan, Torregrosa, Vicente, Saha, Heikki, Reichel, Helmut, Zani, Valter J, Carter, Dave, Messa, Piergiorgio

“…The calcimimetic cinacalcet (Mimpara/Sensipar) simultaneously lowers parathyroid hormone (PTH), phosphorus (P) and calcium (Ca) levels in patients with…”
Get more information

A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia by Schiffer, Charles A., Miller, Kenneth, Larson, Richard A., Amrein, Philip C., Antin, Joseph H., Zani, Valter J., Stone, Richard M.

“…Newly diagnosed patients with acute myeloid leukemia (AML) were randomized to receive either 2.5 or 5 μg/kg/day of pegylated recombinant human megakaryocyte…”
Get full text

The BCL7 gene family: deletion of BCL7B in Williams syndrome by Jadayel, Dalal M., Osborne, Lucy R., Coignet, Lionel J.A., Zani, Valter J., Tsui, Lap-Chee, Scherer, Stephen W., Dyer, Martin J.S.

“…The BCL7A gene, which maps to human chromosome 12q24.13, was cloned through its direct involvement with MYC and IGH in a three-way translocation in a Burkitt…”
Get full text

IgD class switching: identification of a novel recombination site in neoplastic and normal B cells by Kluin, P M, Kayano, H, Zani, V J, Kluin-Nelemans, H C, Tucker, P W, Satterwhite, E, Dyer, M J

“…IgD on normal B lymphocytes usually is co-expressed with IgM. A minority of normal plasma cells and rare B cell malignancies express exclusively IgD…”
Get more information

A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia by Schiffer, Charles A., Miller, Kenneth, Larson, Richard A., Amrein, Philip C., Antin, Joseph H., Zani, Valter J., Stone, Richard M.

“…Newly diagnosed patients with acute myeloid leukemia (AML) were randomized to receive either 2.5 or 5 μg/kg/day of pegylated recombinant human megakaryocyte…”
Get full text